Surveillance of adverse events following immunization in Oman, 2006-2015

Patel, Prakash; Rawahi, Bader Al; Jawari, Athari Al; Abaidani, Idris Al; Al-Abri, Seif

doi:10.26719/2018.24.2.119

Cited by 8 publications

(11 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13 The same was found in Oman after a 10-year analysis of AEs: the wP pentavalent vaccine reported 73.8% of local reactions and 5.6% of systemic reactions. 19 This was also observed by active surveillance in Germany and the Czech Republic, where pain, erythema, and swelling were the most frequent injection site reactions and fever, vomiting, and crying the most frequent systemic reactions. 17 As noted by Zhou (2003) after the change from wP to aP vaccines in the USA, serious AE decreased, as did systemic AE such as fever and neurological reactions such as seizures.…”

Section: Discussionmentioning

confidence: 65%

“… 18 Various studies, including in Chile, have shown that wP pentavalent vaccines are responsible for most AEFI in children and that the group with the highest frequency of reported AE are infants under 1 year of age, due to the fact that they receive the greatest number of vaccines. 16 , 19 , 20 Hence, the fact that hexavalent aP is associated with lower rates of AEFI, being a vaccine frequently administered in children under 2 years of age, aP hexavalent could help to increase confidence toward vaccination.…”

Section: Discussionmentioning

confidence: 99%

“… 13 In this sense, Patel et al reported that SAEs in their research were rare in the hexavalent vaccine, probably due to its acellular component. 19 On the other hand, in the USA, Klein et al (2019) followed a cohort of children under 2 years of age divided into three groups with different aP vaccine schedules with different concomitant vaccines. In this study, the active reporting of SAE was between 0.5 and 3.6%.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

How were DTP-related adverse events reduced after the introduction of an acellular pertussis vaccine in Chile?

Aguirre-Boza

2021

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Chile has a passive surveillance system of adverse events following immunization (AEFI) that allows monitoring and evaluating the safety profile of the vaccines administered. Between 2018 and 2019, the National Immunization Program (NIP) changed from a pentavalent whole-cell pertussis vaccine (wP) to a hexavalent (DTaP-IPV-HepB-Hib) acellular pertussis vaccine (aP) for children <2 years. Objectives: To describe the trend in the frequency of adverse events (AE) records associated to pertussis component vaccines between January 1 st , 2015 and June 30 th , 2020 in infants younger than 2-years-old in Chile, by reviewing the records submitted to the AEFI NIP, stratified by DTP-vaccine type, wP or aP. Materials and methods: This was a retrospective observational study including all AEFI records of DTP (either aP or wP)-containing vaccines in the described sample. A descriptive analysis was performed according to vaccine type and AEFI, using MedDRA terminology. Results: The total number of AEFI reports was 1,697: 815 corresponding to wP vaccines, 417 to aP vaccines, and 465 with unknown type. The reporting rates for the years 2015 to 2020 were 40.1, 56.2, 37.1, 24.7, 19.1, and 12.2 per 100,000 doses administered, respectively. The most reported AEFI were injection site erythema (42.9%), pyrexia (35.7%), and pain at the injection site (29.2%). Among all cases, 5.8% were SAEs (n = 98), 5.9% were SAEs for wP vaccines (n = 48) and 5.3% were for aP vaccines (n = 22). Discussion: A significant decrease in AEFI reports was observed as of 2018, the year that the DTaP-IPV-HepB-Hib was introduced in the NIP.

show abstract

Section: Discussionmentioning

confidence: 65%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

How were DTP-related adverse events reduced after the introduction of an acellular pertussis vaccine in Chile?

Aguirre-Boza

2021

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…This study from Oman where BCG is given at birth to neonates with an almost 100% coverage rate has shown that the average incidence of laboratory-confirmed BCG vaccine-related disease is 9.2 cases per 100,000 vaccinated neonates (0.009%). This is a very low incidence compared with the vaccines’ adverse effects reported in previously published studies as it has been limited only to the moderate to severe forms that would require taking laboratory samples for confirmation and treatment [ 6 , 7 , 8 , 9 ].…”

Section: Discussionmentioning

confidence: 99%

“…The second-decade study found that the BCG vaccine resulted in more adverse events per dose given (37.9/100,000 doses), mostly due to adenitis (82.1%). Since it was passive surveillance data, there may be underreporting of different types of BCG vaccine-related diseases, patient characteristics, and outcomes [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

The Spectrum of Bacille Calmette–Guérin Diseases in Children—A Decade of Data from Neonatal Vaccination Settings

Busaidi

Al-Jardani

et al. 2021

Vaccines

View full text Add to dashboard Cite

In this paper, we present a multicentre record-based descriptive study used to estimate the incidence and characterize the spectrum of confirmed bacille Calmette–Guérin (BCG) vaccine-related disease among children in Oman. This study included all children (age ≤ 14 years) who had culture and/or polymerase chain reaction (PCR)-confirmed BCG disease from January 2006 to December 2018, as identified from Central Public Health Laboratory data and International Classification of Diseases coding of an electronic patient information system. In total, 88 children confirmed to have BCG disease were included in the study, making an average incidence of 9.2 cases per 100,000 vaccinated neonates. The males comprised 65.9%, Omanis 93.2%, and the median age of presentation was 4 months in children with BCG disease. The most common type of disease was BCG abscesses (72.4%). Children with immunodeficiency and those presenting within 6 months were found to have a more severe and disseminated disease. In total, 28 children had immunodeficiency. The age of presentation and type of BCG disease was significantly associated with immunodeficiency status. The majority of cases required therapy (both medical and surgical) and recovered well. The incidence of laboratory-confirmed BCG vaccine-related disease was low in Oman supporting continuing the use of the BCG vaccination practice at birth.

show abstract

Surveillance of adverse events following the introduction of inactivated poliovirus vaccine made from Sabin strains (sIPV) to the Chinese EPI and a comparison with adverse events following inactivated poliovirus vaccine made from wild strains (wIPV) in Jiangsu, China

Kang

Tang

Wang

et al. 2021

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Surveillance of adverse events following immunization in Oman, 2006-2015

Cited by 8 publications

References 2 publications

How were DTP-related adverse events reduced after the introduction of an acellular pertussis vaccine in Chile?

How were DTP-related adverse events reduced after the introduction of an acellular pertussis vaccine in Chile?

The Spectrum of Bacille Calmette–Guérin Diseases in Children—A Decade of Data from Neonatal Vaccination Settings

Surveillance of adverse events following the introduction of inactivated poliovirus vaccine made from Sabin strains (sIPV) to the Chinese EPI and a comparison with adverse events following inactivated poliovirus vaccine made from wild strains (wIPV) in Jiangsu, China

Contact Info

Product

Resources

About